Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Abstract
The growth factor brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin-related kinase receptor type B (TRKB) are actively produced and trafficked in multiple regions in the adult brain, where they influence neuronal activity, function and survival throughout life. The diverse presence and activity of BDNF suggests a potential role for this molecule in the pathogenesis and treatment of both neurological and psychiatric disorders. This article reviews the current understanding and future directions in BDNF-related research in the central nervous system, with an emphasis on the possible therapeutic application of BDNF in modifying fundamental processes underlying neural disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both synthetic and endogenous Aβ42 monomers in nanomolar concentrations stimulated activity of CREB and BDNF, which have key roles in regulation of gene expressions related to neuronal functions and survival in normal brains.
“In addition, both synthetic and endogenous Aβ42 monomers in nanomolar concentrations stimulated the activity of cyclic adenosine monophosphate (cAMP) responsive element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF), which possessed key roles in the regulation of gene expressions related to neuronal functions and survival in normal brains.371,372”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [372]
Therapeutic use of BDNF can directly or indirectly modulate changes within the brain.
“Some promising results have been published from studies showing that therapeutic use of BDNF can, directly or indirectly, modulate changes within the brain [195].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [195]
The citation lists haven’t been fetched yet
References 168 · Cited by 867
- Authors
- Nagahara, A. H., & Tuszynski, M. H.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Tuszynski, Mark H.
- ORCID
- Tuszynski, Mark H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 209-219
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2009582310
- Cited by
- 867
- References
- 168
- Citations by year
- 2026: 35 · 2025: 39 · 2024: 51 · 2023: 65 · 2022: 61 · 2021: 49 · 2020: 56 · 2019: 58 · 2018: 66 · 2017: 59 · 2016: 60 · 2015: 53 · 2014: 63 · 2013: 69 · 2012: 64
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (P01AG010435, AG10435)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- brain-derived neurotrophic factor, TrkB receptor, Alzheimer's disease, neurological disorders, mental illness, neurotrophic therapy, neuronal survival, neurodegeneration
- MeSH terms
- Adult, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Mental Disorders, Cognition, Humans, Huntington Disease, Metabolic Diseases, Nervous System Diseases, Parkinson Disease, Spinal Cord Injuries, Genetic Therapy, Brain-Derived Neurotrophic Factor, Stroke, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
